In vitro and in vivo antiangiogenic activity of a novel deca-peptide derived from human tissue-type plasminogen activator kringle 2

Biochemical and Biophysical Research Communications

Volumn 396, Issue 4, 2010, Pages 1012-1017

  Su, Li ^a   Xu, Xun ^a   Zhao, Hui ^a   Gu, Qing ^a   Zou, Haidong ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Angiogenesis inhibitor; Kringle domain; Peptide; Tissue type plasminogen activator

Indexed keywords

ARGINYLASPARAGINYLPROLYLASPARTYLALANYLGLYCYLASPARTYLLYSYLPROLYLTRYPTOPHAN; ARGINYLASPARAGINYLPROLYLASPARTYLGLYCYLASPARTYLALANYLLYSYLPROLYLTRYPTOPHAN; SYNTHETIC PEPTIDE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CORNEA; ENDOTHELIUM, VASCULAR; HUMANS; KRINGLES; MALE; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953293453     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.048     Document Type: Article

References (26)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
2. Shibuya M., and Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312 (2006) 549-560
3. Karamysheva A.F. Mechanisms of angiogenesis. Biochemistry 73 (2008) 751-762
4. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
5. Yamaguchi N., Anand-Apte B., Lee M., Sasaki T., Fukai N., Shapiro R., Que I., Lowik C., Timpl R., and Olsen B.R. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18 (1999) 4414-4423
6. Kim H.K., Lee S.Y., Oh H.K., Kang B.H., Ku H.J., Lee Y., Shin J.Y., Hong Y.K., and Joe Y.A. Inhibition of endothelial cell proliferation by the recombinant kringle domain of tissue-type plasminogen activator. Biochem. Biophys. Res. Commun. 304 (2003) 740-746
7. Lee B.H., Kim H.K., and Joe Y.A. The kringle domain of tissue-type plasminogen activator inhibits extracellular matrix-induced adhesion and migration of endothelial cells. Biosci. Biotechnol. Biochem. 72 (2008) 2303-2308
8. Shim B.S., Kang B.H., Hong Y.K., Kim H.K., Lee I.H., Lee S.Y., Lee Y.J., Lee S.K., and Joe Y.A. The kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth. Biochem. Biophys. Res. Commun. 327 (2005) 1155-1162
9. Carroll V.A., Nikitenko L.L., Bicknell R., and Harris A.L. Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 736-741
10. Cao Y., Cao R., and Veitonmäki N. Kringle structures and antiangiogenesis. Curr. Med. Chem.: Anticancer Agents 2 (2002) 667-681
11. Kuba K., Matsumoto K., Date K., Shimura H., Tanaka M., and Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 60 (2000) 6737-6743
12. Kim K.S., Hong Y.K., Joe Y.A., Lee Y., Shin J.Y., Park H.E., Lee I.H., Lee S.Y., Kang D.K., Chang S.I., and Chung S.I. Antiangiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells. J. Biol. Chem. 278 (2003) 11449-11456
13. Sulochana K.N., and Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr. Pharm. Des. 13 (2007) 2074-2086
14. Sulochana K.N., Fan H.P., Jois S., Subramanian V., Sun F., Kini R.M., and Ge R. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J. Biol. Chem. 280 (2005) 27935-27948
15. Yi Z.F., Cho S.G., Zhao H., Wu Y.Y., Luo J., Li D., Yi T., Xu X., Wu Z., and Liu M. A novel peptide from human apolipoprotein (a) inhibits angiogenesis and tumor growth by targeting c-Scr phosphorylation in VEGF-induced human umbilical endothelial cells. Int. J. Cancer 124 (2009) 843-852
16. Kang B.H., Shim B.S., Lee S.Y., Lee S.K., Hong Y.K., and Joe Y.A. Potent anti-tumor and prolonged survival effects of E. coli-derived non-glycosylated kringle domain of tissue-type plasminogen activator. Int. J. Oncol. 28 (2006) 361-367
17. Oh H.-K., Ha J.-M., O E., Lee B.H., Lee S.K., Shim B.-S., Hong Y.-K., and Joe Y.A. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2. Cancer Res. 67 (2007) 4851-4859
18. Zhao H., Jin H.Y., Li Q., Gu Q., Zheng Z., Wu H.X., Ye S.W., Sun X.D., Xu X., and Ho P.C.P. Inhibition of pathologic retinal neovascularization by a small peptide derived from human apolipoprotein(a). Invest. Ophthalmol. Vis. Sci. 50 (2009) 5384-5395
19. Kim H.K., Oh D.S., Lee S.B., Ha J.M., and Joe Y.A. Antimigratory effect of TK1-2 is mediated in part by interfering with integrin α2β1. Mol. Cancer Ther. 7 (2008) 2133-2141
20. Senger D.R., Claffey K.P., Benes J.E., Perruzzi C.A., Sergiou A.P., and Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins. Proc. Natl. Acad. Sci. USA 94 (1997) 13612-13617
21. Senger D.R., Perruzzi C.A., Streit M., Koteliansky V.E., de Fougerolles A.R., and Detmar M. The α1β1 and α2β1 integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am. J. Pathol. 160 (2002) 195-204
22. Staatz W.D., Fok K.F., Zutter M.M., Adams S.P., Rodriguez B.A., and Santoro S.A. Identification of a tetrapeptide recognition sequence for the α2β1 integrin in collagen. J. Biol. Chem. 266 (1991) 7363-7367
23. Kim H.K., and Joe Y.A. DGDA, a local sequence of the kringle 2 domain, is a functional motif of the tissue-type plasminogen activator's antiangiogenic kringle domain. Biochem. Biophys. Res. Commun. 391 (2010) 166-169
24. Bainbridge J.W.B., Jia H., Bagherzadeh A., Selwood D., Ali R.R., and Zachary I. A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo. Biochem. Biophys. Res. Commun. 302 (2003) 793-799
25. Cattaneo M.G., Pola S., Francescato P., Chillemi F., and Vicentini L.M. Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp. Cell Res. 283 (2003) 230-236
26. Rüegg C., Hasmim M., Lejeune F.J., and Alghisi G.C. Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim. Biophys. Acta 1765 (2006) 155-177